Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Andexanet Alfa Versus Pcc Products For Factor Xa Inhibitor Bleeding: A Systematic Review With Meta-Analysis, C. Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrian V. Hernandez, William L. Baker, Paul P. Dobesh, Heleen Van Haalen, Kirsty Rhodes, Craig I. Coleman
Andexanet Alfa Versus Pcc Products For Factor Xa Inhibitor Bleeding: A Systematic Review With Meta-Analysis, C. Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrian V. Hernandez, William L. Baker, Paul P. Dobesh, Heleen Van Haalen, Kirsty Rhodes, Craig I. Coleman
Journal Articles: Pharmacy Practice
Previous meta-analyses assessed andexanet alfa (AA) or prothrombin complex concentrate (PCC) products for the treatment of Factor Xa inhibitor (FXaI)-associated major bleeding. However, they did not include recent studies or assess the impact of the risk of bias. We conducted a systematic review with meta-analysis on the effectiveness of AA versus PCC products for FXaI-associated major bleeding, inclusive of the studies' risk of bias. PubMed and Embase were searched for comparative studies assessing major bleeding in patients using FXaI who received AA or PCC. We used the Methodological Index for NOn-Randomized Studies (MINORS) checklist and one question from the Joanna …